Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease

Committee papers Declaration of Interest (PDF 114 KB)

Final draft guidance

Final appraisal document (PDF 229 KB)

Committee papers - ACM2 (PDF 2.57 MB)

Draft guidance

Appraisal consultation document (online commenting)

Appraisal consultation document (PDF version) (PDF 242 KB)

Committee papers - ACM1 (PDF 5.28 MB)

Final stakeholder list (PDF 188 KB)

Final appraisal document - TA558 (PDF 370 KB)

Final appraisal document - managed access agreement - TA558 (PDF 617 KB)

Committee papers (FAD) - TA558 (PDF 3.21 MB)

Public committee slides (ACM2) - TA558 (PDF 1.62 MB)

Appraisal consultation document (PDF version) - TA558 (PDF 343 KB)

Committee papers (ACD) - TA558 (PDF 21.25 MB)

Public committee slides (ACM1-clinical) - TA558 (PDF 1.4 MB)

Consultation document - draft scope TA558 (PDF 317 KB)

Consultation document - draft matrix TA558 (PDF 259 KB)

Final scope - TA558 (PDF 226 KB)

Final stakeholder list - TA558 (PDF 259 KB)

NICE's response to comments on the draft scope and provisional stakeholder list - TA558 (PDF 246 KB)